Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,500.00
-10.00 (-0.18%)
At close: Jun 4, 2026
Market Cap131.73B +2.8%
Revenue (ttm)269.64B +14.0%
Net Income347.40M -84.9%
EPS14.51 -84.9%
Shares Out 23.91M
PE Ratio379.18
Forward PEn/a
Dividend50.00 (0.88%)
Ex-Dividend DateDec 29, 2025
Volume48,984
Open5,380.00
Previous Close5,510.00
Day's Range5,380.00 - 5,660.00
52-Week Range4,755.00 - 9,300.00
Beta0.37
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an... [Read more]

Sector Healthcare
Founded 1987
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 214390
Full Company Profile

Financial Performance

In 2025, Kyongbo Pharmaceutical's revenue was 264.10 billion, an increase of 10.71% compared to the previous year's 238.56 billion. Earnings were 182.29 million, a decrease of -96.07%.

Financial Statements